Antibody-drug Conjugates(ADC)


ADCs are one of the most promising new classes of drugs for treating cancers that are difficult to treat with traditional chemotherapy and believed to be the "next big thing" in the field of cancer therapy. They have the potential to revolutionize the way cancer is treated by targeting only cancer cells while sparing normal cells. ADCs are highly selective for cancer cells, reducing the side effects associated with traditional chemotherapy and radiation. They do not an entire organ or organ systems, but only target specific cancer cells, reducing toxicity to healthy tissues. ADCs also have the potential to penetrate the tumor microenvironment, theoretically resulting in better tumor response rates.


ADC mechanism of action (Source from:


Antibody-drug conjugates (ADCs) harness the power of antibodies to target drugs to specific cells, resulting in improved therapeutic efficacy and better toxicity profiles than traditional cancer therapies. ADCs link an antibody to a potent cytotoxic drug via a biodegradable linker, enabling the antibody to recognize and bind to cell surface targets, and the drug to kill those cells. ADCs are designed to target cell-surface markers typical of cancer cells, such as overexpressed proteins. The antibody portion of the ADC binds to the cell surface marker, while the drug portion remains tethered to the antibody, localized to a small area of the cell membrane. Once targeted to the surface of the cancer cell, the ADC delivers a high dose of the drug, killing the cell.


At this stage of clinical development, existing ADCs have demonstrated clinical benefits, but have yet to show substantial improvement in overall survival. However, clinical trials and preclinical studies continue to be conducted to address questions related to efficacy and toxicity. As the science behind ADCs continues to evolve, more targeted, potent and safe therapeutic options for treating cancer are being developed. It is an exciting area of research, and one that has the potential to provide much needed hope for cancer patients.


At ALL Chemistry Inc., we are proud to offer our customers our state of the art Antibody-drug Conjugates technologies. We understand that each customer's needs are different and that is why we are committed to providing a tailored solution for each and every one. Our Antibody-drug Conjugates technologies are based on the latest in scientific research and provide our customers with the highest quality results. Utilizing cutting edge advancements in the field, our team of experts are able to provide highly optimized individual conjugate linkers, reagents, drug-dye combinations and data analysis services. All of our projects are completed quickly and efficiently, providing superior results with the utmost precision and accuracy.



ADC structure (Source from ADCREVIEW)


Our team of experienced personnel are dedicated to providing superior customer service. Our customer service staff has a deep understanding of Antibody-drug Conjugates technology, ensuring that each customer's project receives the attention it deserves. With our friendly staff, responsive support, and comprehensive service packages, we guarantee that no customer will be left feeling underwhelmed or neglected.


At ALL Chemistry Inc. we are dedicated to providing our customers with the highest quality Antibody-drug Conjugates technology. From our passionate customer service staff to our cutting edge technology, we guarantee that no project is too great or too small. So if you're looking for an experienced and reliable provider of Antibody-drug Conjugates technology, we at ALL Chemistry Inc. are here to help!


Additional Services


-- ADC Antibody Screening

-- ADC Analytical Characterization and Validation

-- ADC Fill and Finish

-- Antibody Conjugation Chemistry

-- Linker and Payload Synthesis


Our Advantages


-- Experienced team

-- Advanced technologies and methods

-- High-quality, low-cost products

-- Personalized service

-- Strict quality control

Documents Download

Contact Us

Telephone:+1 609 531 0668 ,